A potential rate hike kept investor enthusiasm in check. The markets opened flat with the Dow adding 2 points to 22,414 while Nasdaq lost 8 points to 6,448.
On the upside
Anadarko Petroleum (NYSE: APC) will repurchase up to $2.5 billion worth of stock.
The Food and Drug Administration granted orphan drug designation to Amicus Therapeutics' (Nasdaq: FOLD) ATB200/AT2221.
Calgon Carbon (NYSE: CCC) will be acquired by Kuraray for a premium of approximately $1.1 billion in cash.
On the downside
Nvidia (Nasdaq: NVDA) client Tesla (Nasdaq: TSLA) will work with Advanced Micro Devices (Nasdaq: AMD) to develop an artificial intelligence chip for autonomous cars.
Chevron (NYSE: CVX) terminated a drilling contract with Transocean (NYSE: RIG) for the ultra-deepwater drillship Discoverer Clear Leader.
Acceleron Pharma (Nasdaq: XLRN) priced its public offering of more than 5.4 million shares of common stock at the discounted price of $37.00 per share.
In the broad market, advancing issues barely edged out decliners by a slim margin on the NYSE while decliners outpaced advancers by 5 to 4 on Nasdaq. The broader S&P 500 eased a point to 2,507. Bitcoin plunged $73 to $3,864.
